Itālija - itāļu - AIFA (Agenzia Italiana del Farmaco)

astra farmaceutici s.p.a. - nitrosouree - nitrosouree

Itālija - itāļu - AIFA (Agenzia Italiana del Farmaco)

les laboratoires servier - fotemustina - fotemustina

Itālija - itāļu - AIFA (Agenzia Italiana del Farmaco)

accord healthcare, s.l.u. - carmustina - carmustina

Eiropas Savienība - itāļu - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - carmustina - hodgkin disease; lymphoma, non-hodgkin - agenti antineoplastici - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Itālija - itāļu - AIFA (Agenzia Italiana del Farmaco)

waymade bv - carmustina - carmustina

Itālija - itāļu - AIFA (Agenzia Italiana del Farmaco)

tillomed italia srl - carmustina - carmustina

Itālija - itāļu - AIFA (Agenzia Italiana del Farmaco)

eugia pharma (malta) limited - carmustina - carmustina

Eiropas Savienība - itāļu - EMA (European Medicines Agency)

dompé biotec s.p.a. - pegfilgrastim - neutropenia; cancer - immunostimolanti, - riduzione della durata della neutropenia e dell'incidenza di neutropenia febbrile in pazienti trattati con chemioterapia citotossica per neoplasie (con l'eccezione di croniche mieloide leucemia e delle sindromi mielodisplastiche).

Eiropas Savienība - itāļu - EMA (European Medicines Agency)

teva b.v. - lipegfilgrastim - neutropenia - immunostimolanti, , stimolante le colonie di fattori - lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Eiropas Savienība - itāļu - EMA (European Medicines Agency)

amgen europe b.v. - pegfilgrastim - neutropenia; cancer - immunostimolanti, - riduzione della durata della neutropenia e dell'incidenza di neutropenia febbrile in pazienti trattati con chemioterapia citotossica per neoplasie (con l'eccezione di croniche mieloide leucemia e delle sindromi mielodisplastiche).